Veracyte, Inc. (VCYT)

NGM – Real vaqt narxi. Valyuta: USD

39.56

-0.14 (-0.35%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow by double-digit rates.

07.05.2026

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

06.05.2026

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

06.05.2026

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.

05.05.2026

Veracyte Announces First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets,” said Marc Stapley, Veracyte's CEO. “Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approac.

05.05.2026

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

28.04.2026

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Veracyte Announces First Quarter 2026 Financial Results

28.04.2026

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

16.03.2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.

25.02.2026

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte's chief executive officer. “We are achieving this growth while mai.

Veracyte, Inc. (VCYT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veracyte, Inc. (VCYT)

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte Announces First Quarter 2026 Financial Results

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Videolar

No Data

Press-relizlar

Veracyte Announces First Quarter 2026 Financial Results

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte Announces First Quarter 2026 Financial Results

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Videolar

No Data

Press-relizlar

Veracyte Announces First Quarter 2026 Financial Results

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Veracyte, Inc. (VCYT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veracyte, Inc. (VCYT)

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte Announces First Quarter 2026 Financial Results

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Videolar

No Data

Press-relizlar

Veracyte Announces First Quarter 2026 Financial Results

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte Announces First Quarter 2026 Financial Results

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Videolar

No Data

Press-relizlar

Veracyte Announces First Quarter 2026 Financial Results

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results